Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Mary Mackle"'
Autor:
Yuki Mukai, Robert Lupinacci, Stephen Marder, Mary Mackle, Linda Snow-Adami, Tiffini Voss, Sean Smith, Michael Egan
Publikováno v:
Biological Psychiatry. 91:S305
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c883d4d493a196122ce51123af3858ae
https://doi.org/10.1016/j.biopsych.2022.02.771
https://doi.org/10.1016/j.biopsych.2022.02.771
Autor:
Xiao Wu, Maju Mathews, Armin Szegedi, Sung Yun Yu, Suresh Durgam, Mary Mackle, Ronald P. Landbloom
Publikováno v:
American Journal of Psychiatry. 175:71-79
The authors determined the efficacy and safety of asenapine in preventing recurrence of any mood episode in adults with bipolar I disorder.Adults with an acute manic or mixed episode per DSM-IV-TR criteria were enrolled in this randomized, placebo-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b6a38c2b87946b76fc660c9ac0f985
https://doi.org/10.1176/appi.ajp.2017.16040419
https://doi.org/10.1176/appi.ajp.2017.16040419
Publikováno v:
Journal of Affective Disorders. 207:384-392
Background Asenapine (ASN) is approved in the United States as monotherapy and adjunctive therapy (to lithium or valproate) in adults with bipolar mania, and as monotherapy in pediatric patients with bipolar mania. This is the first long-term study e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4215deb3a94169e4da193b5bf7ac440
Autor:
Kiki D. Chang, Mary Mackle, Linda Snow-Adami, Robert L. Findling, Ronald L. Landbloom, Suresh Durgam, Xiao Wu
Publikováno v:
Paediatric Drugs
Background Sublingually administered asenapine was approved in March 2015 by the United States Food and Drug Administration for patients aged 10–17 years with an acute manic or mixed episode associated with bipolar I disorder (BP-1). This is the fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04008ab46d8805ed0e3b675ef0bf2150
https://doi.org/10.1007/s40272-016-0184-2
https://doi.org/10.1007/s40272-016-0184-2
Autor:
Linda Snow-Adami, Xiao Wu, Roger S. McIntyre, Mary Mackle, Maju Mathews, Ronald L. Landbloom, Linda J. Kelly, Carla Hundt
Publikováno v:
Journal of Affective Disorders. 190:103-110
Background Asenapine is an atypical antipsychotic for acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. The recommended asenapine starting dose is 10 mg bid with the option to reduce the dose to 5 mg bid if need
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe5a49895ffc9d2de0c58005214c052c
https://doi.org/10.1016/j.jad.2015.06.059
https://doi.org/10.1016/j.jad.2015.06.059
Autor:
Ronald L. Landbloom, Kiki D. Chang, Qi Zhu, Mary Mackle, Sabine Braat, Robert L. Findling, Maju Mathews, Janelle Koppenhaver, Armin Szegedi
Publikováno v:
Journal of the American Academy of Child & Adolescent Psychiatry. 54(12):1032-1041
ObjectiveTo evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently in manic or mixed episodes.MethodIn this double-blind, placebo-controlled, international trial, patients were randomized 1:1:1:1 to pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a40617efc13c3f9e29110bd87c80568
Publikováno v:
Neuropsychiatric Disease and Treatment
Suresh Durgam,1 Ronald P Landbloom,2 Mary Mackle,2 Xiao Wu,1 Maju Mathews,3 Henry A Nasrallah4 1Allergan Inc, Jersey City, 2Merck, Whitehouse Station, 3Forest Research Institute (now Allergan), Jersey City, NJ, 4Saint Louis University School of Medic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8884e23c4081199ed92ac76668fa335
https://www.dovepress.com/exploring-the-long-term-safety-of-asenapine-in-adults-with-schizophren-peer-reviewed-article-NDT
https://www.dovepress.com/exploring-the-long-term-safety-of-asenapine-in-adults-with-schizophren-peer-reviewed-article-NDT
Weight Change and Metabolic Effects of Asenapine in Patients With Schizophrenia and Bipolar Disorder
Autor:
Ronald P. Landbloom, Linda Snow-Adami, Armin Szegedi, David E. Kemp, Mary Mackle, Pilar Cazorla, Jun Zhao
Publikováno v:
The Journal of Clinical Psychiatry. 75:238-245
OBJECTIVE To describe weight changes and metabolic effects of asenapine compared with placebo and olanzapine in adults. METHOD Post hoc analyses were performed using data from 17 asenapine trials (13 schizophrenia and 4 bipolar mania trials) with pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44b383bc41fd4e411eddb344ba6b2d3
https://doi.org/10.4088/jcp.12m08271
https://doi.org/10.4088/jcp.12m08271
Autor:
Xiao Wu, Mary Mackle, Linda J. Kelly, Ronald P. Landbloom, Roger S. McIntyre, Maju Mathews, Linda Snow-Adami, Carla Hundt
Publikováno v:
CNS spectrums. 22(4)
ObjectiveEvaluate the efficacy and safety of asenapine 2.5 mg twice daily (bid; n=97) or 5 mg bid (n=113) versus placebo (n=101) in adults with acute exacerbation of schizophrenia.MethodsAdults with Diagnostic and Statistical Manual of Mental Disorde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b49b8618d7cb6758d64fe54bfca9314
https://pubmed.ncbi.nlm.nih.gov/27821210
https://pubmed.ncbi.nlm.nih.gov/27821210
Autor:
Armin Szegedi, Mary Mackle, Hein Fennema, Pilar Cazorla, Pierre Verweij, Wilbert van Duijnhoven
Publikováno v:
The Journal of Clinical Psychiatry. 73:1533-1540
CONTEXT Asenapine is an approved treatment for schizophrenia in the United States. OBJECTIVE Meta-analyses were conducted to evaluate the efficacy of asenapine in acute schizophrenia compared with placebo and other antipsychotics. DATA SOURCES Four a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2440d6bca6f174d9f0db398b9879499d
https://doi.org/10.4088/jcp.11r07596
https://doi.org/10.4088/jcp.11r07596